TheraSphere for the Treatment of Liver Metastases
Ontology highlight
ABSTRACT: This study will evaluate Liver Progression Free Survival (PFS) and safety of TheraSphere treatment at doses of 120 Gy +/1 10% in patients at least 18 years of age diagnosed with metastatic disease to the liver that cannot be treated or is progressing following treatment with systemic or other liver-directed therapies.
DISEASE(S): Neoplasm Metastasis,Carcinoma, Neuroendocrine,Colorectal Cancer,Colorectal Neoplasms
PROVIDER: 2042885 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA